Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study
AB Gottlieb, M Lebwohl, S Shirin, A Sherr… - Journal of the American …, 2000 - Elsevier
Background: OKTcdr4a (IMUCLONE) is a humanized anti-CD4 IgG4 monoclonal antibody
that retains the binding and in vitro immunosuppressive properties of the parent murine
antibody. Psoriasis is a chronic disease for which treatment with multiple doses of
monoclonal antibodies is likely to be required for adequate control. Objective: This study
was performed to test the efficacy and safety of OKTcdr4a, given in sequential courses over
a period of several weeks, in the treatment of moderate to severe psoriasis vulgaris …
that retains the binding and in vitro immunosuppressive properties of the parent murine
antibody. Psoriasis is a chronic disease for which treatment with multiple doses of
monoclonal antibodies is likely to be required for adequate control. Objective: This study
was performed to test the efficacy and safety of OKTcdr4a, given in sequential courses over
a period of several weeks, in the treatment of moderate to severe psoriasis vulgaris …